A detailed history of Wellington Management Group LLP transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 65,157 shares of HALO stock, worth $3.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65,157
Previous 397,781 83.62%
Holding current value
$3.13 Million
Previous $20.8 Million 82.1%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$51.3 - $64.42 $17.1 Million - $21.4 Million
-332,624 Reduced 83.62%
65,157 $3.73 Million
Q2 2024

Aug 13, 2024

BUY
$37.81 - $52.4 $5.76 Million - $7.99 Million
152,387 Added 62.1%
397,781 $20.8 Million
Q1 2024

May 15, 2024

BUY
$33.68 - $41.95 $8.26 Million - $10.3 Million
245,394 New
245,394 $9.98 Million
Q4 2023

Feb 12, 2024

BUY
$33.32 - $42.1 $6.03 Million - $7.61 Million
180,856 New
180,856 $6.68 Million
Q3 2023

Nov 14, 2023

BUY
$36.46 - $44.03 $1.06 Million - $1.28 Million
28,958 Added 22.84%
155,731 $5.95 Million
Q2 2023

Aug 14, 2023

BUY
$30.28 - $38.74 $3.84 Million - $4.91 Million
126,773 New
126,773 $4.57 Million
Q4 2022

Feb 13, 2023

SELL
$40.06 - $59.44 $2.38 Million - $3.53 Million
-59,322 Reduced 16.65%
296,997 $16.9 Million
Q3 2022

Nov 14, 2022

BUY
$38.53 - $51.78 $6.48 Million - $8.71 Million
168,195 Added 89.41%
356,319 $14.1 Million
Q2 2022

Aug 15, 2022

BUY
$37.35 - $48.3 $7.03 Million - $9.09 Million
188,124 New
188,124 $8.28 Million
Q1 2020

May 14, 2020

SELL
$13.9 - $21.83 $244,820 - $384,491
-17,613 Closed
0 $0
Q4 2019

Feb 11, 2020

BUY
$14.93 - $19.53 $262,962 - $343,981
17,613 New
17,613 $312,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.69B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.